Nervonik Secures $52.5M Series B Funding to Develop Neuromodulation Platform

The company is developing a neuromodulation platform aimed at treating chronic pain through targeted nerve stimulation.

Nervonik, a Los Angeles-based medical device company focused on peripheral nerve stimulation technologies, has raised $52.5 million in an oversubscribed Series B funding round. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital.

The company is developing a neuromodulation platform aimed at treating chronic pain through targeted nerve stimulation. Its system, which includes proprietary sensing capabilities, is currently under development and has not yet received clearance or approval from the U.S. Food and Drug Administration.

According to the company, the fresh capital will be directed toward advancing clinical programs and supporting the development and commercialization of its peripheral nerve stimulation system. The focus will remain on refining its technology and preparing for broader market entry.

Commenting on the funding, Dr. Anthony Natale, partner at Amzak Health, noted that peripheral nerve stimulation is entering a key phase of clinical expansion. He highlighted increasing clinical evidence and growing adoption of the approach in chronic pain treatment. He also stated that Nervonik’s platform is positioned to potentially improve patient experience, adding that the firm is expected to benefit from rising interest in neuromodulation-based therapies.

The latest funding follows Nervonik’s $13 million Series A round closed last year, along with earlier SAFE and convertible note investments totaling $4.4 million from Shangbay Capital, Camford Capital, Joyance Partners, Life Science Angels, and Seraph Group.

The neuromodulation sector has seen increasing investor activity. Earlier this month, Cala Health, another player in wearable neuromodulation therapy for tremors, secured $50 million in growth capital. The company had also completed an oversubscribed $50 million growth round in 2024, following earlier funding rounds in 2019 and 2021.

Nervonik’s latest raise adds to continued funding momentum in bioelectronic medicine and nerve stimulation technologies targeting neurological and chronic pain conditions.

Stay tuned for more such updates on Digital Health News